AEON Biopharma, Inc. (AEON)

AEON Biopharma is developing ABP-450 (prabotulinumtoxinA), a branded biosimilar to BOTOX, for therapeutic indications in neuromuscular conditions. The company aims to expand patient access to botulinum toxin treatments by leveraging FDA's biosimilar pathway and an established manufacturing platform to address cost and coverage limitations in the market.